Keywords: sanofi-aventis, 2nd-qtr, profit, falls, generics, take, toll
Sanofi-Aventis 2nd-qtr profit falls as generics take toll on Eloxati and Ambien
Article | 06 August 2007
Leading French pharmaceutical group Sanofi-Aventis disappointed investors, posting second-quarter 2007 results which were below consensus estimates. Moreover, its announcement of an ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
